Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
Future Oncology (London, England)|August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studiesLawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate CancerEric J Small, Raymond S Lance, Thomas A Gardner, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2021
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trialDavid F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE TrialsEmmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, et al.
Prostate Cancer and Prostatic Diseases|November 22, 2017
Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice settingJay White, B Vittal Shenoy, Ronald F Tutrone, et al.
The Prostate|August 12, 2020
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for cliniciansNeal D Shore, Charles G Drake, Daniel W Lin, et al.
Future Oncology (London, England)|June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language reviewPaul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Urologic Oncology|March 26, 2017
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancerNicholas M Donin, Karim Chamie, Andrew T Lenis, et al.
Pageof 4